Aimmune Therapeutics

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Aimmune Therapeutics sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 8 completed later-stage tilt top decile by trial count

Aimmune Therapeutics: 10 sponsored US clinical trials, 1 recruiting.

Aimmune Therapeutics sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 8 completed. 6 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peanut Allergy, with 5 trials.

Top-decile sponsor footprint

Aimmune Therapeutics ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING NA

Aimmune Longitudinal Collaboration Study

NCT07218640
TERMINATED Phase 2

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

NCT04056299
COMPLETED Phase 3

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization

NCT03736447
COMPLETED Phase 3

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

NCT03292484
COMPLETED Phase 3

AR101 Real-World Open-Label Extension Study

NCT03337542
COMPLETED Phase 3

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)

NCT03126227
COMPLETED Phase 3

PALISADE Follow-on Study (ARC004)

NCT02993107
COMPLETED Phase 3

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

NCT02635776
COMPLETED Phase 2

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

NCT02198664
COMPLETED Phase 2

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT

NCT01987817

Phase Distribution

PhaseTrial count
Phase 2 3
Phase 3 6

Therapeutic Areas

Peanut Allergy 5
Dietary Fiber 1
Microbiome Composition 1
Stool Spore Colony Forming Units 1
Stress 1

Where Aimmune Therapeutics enrollment is open (later-stage tilt)

1 recruiting of 10 indexed (10% open); 8 completed (80%).

Phase mix: 6 late (III/IV) vs 3 early (I/II) (later-stage heavy).

Top condition: Peanut Allergy (5 trials), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Aimmune Therapeutics: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Aimmune Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Aimmune TherapeuticsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)Ascension Health
Aimmune Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aimmune Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Aimmune Therapeutics page

10 registered trials is a research-attention snapshot, not an endorsement of Aimmune Therapeutics or any single study.

  • 1 of Aimmune Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Peanut Allergy is the condition Aimmune Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peanut Allergy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aimmune Therapeutics pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.